Orodispersible dosage unit containing an estetrol component
The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 μg of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 μm to 50 μm. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration.
1. A process of making an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg and containing at least 100 μg of an estetrol component selected from one or more of estetrol and estetrol esters, wherein the dosage unit consists of (i) 0.1-25 wt % estetrol particles, wherein the estetrol particles comprise the estetrol component in an amount of at least 80 wt. % of the particles and (ii) 75-99.9 wt. % of one or more pharmaceutically acceptable ingredients, the process comprising:
providing estetrol particles having a volume median diameter of from 2 μm to 50 μm and comprising the estetrol component in an amount of at least 80 wt. % of the estetrol particles;
mixing the estetrol particles with one or more granulation excipients to produce a granulation mixture;
mixing the granulation mixture with a granulation liquid to produce estetrol-containing granules, wherein the granulation liquid comprises a liquid solvent in an amount of at least 60 wt. %;
removing liquid solvent from the estetrol-containing granules to produce dry estetrol-containing granules;
optionally, mixing the dry granules with one or more tabletting excipients to produce a mixture; and
forming the dry granules or the mixture into a solid dosage unit having a weight between 30 and 1,000 mg and containing at least 100 μg of the estetrol component, wherein the estetrol particles make up 0.1-25 wt. % of the dosage unit.
2. The process according to claim 1 , wherein the estetrol particles have a volume median diameter of 3-35 μm.
3. The process according to claim 1 , wherein the granulation mixture contains a disintegrating agent in an amount of 0.1-20 wt. % selected from one or more of modified starches, crosslinked PVP, and crosslinked carmellose.
4. The process according to claim 1 , wherein the granulation mixture is produced by combining the estetrol particles with the one or more granulation excipients in a weight ratio that is in a range of from 1:4 to 1:1,000.
5. The process according to claim 1 , wherein the estetrol-containing granules are produced by mixing the granulation mixture with the granulation liquid in a weight ratio that is in a range of from 0.5:1 to 20:1.
6. The process according to claim 1 , wherein the estetrol-containing granules are produced by mixing the granulation mixture with the granulation liquid in a high shear granulator, a low shear granulator, or a fluidized bed granulator.
7. The process according to claim 1 , wherein the granulation liquid contains a polar solvent in an amount of at least 60 wt. % selected from one or more of water, methanol, ethanol, isopropanol, and acetone.
8. The process according to claim 1 , wherein the granulation liquid contains a polar solvent in an amount of at least 60 wt. % selected from one or more of water and ethanol.
9. The process according to claim 7 , wherein the polar solvent contains at least 80 wt. % water.
10. The process according to claim 1 , wherein the granulation liquid contains a binder in an amount of 0.2-50 wt. % selected from one or more of cellulose derivatives, starch, starch derivatives, polyvinyl alcohol, polyvinylpyrrolidone, agar, gelatin, guar gum, gum Arabic, alginate, polyethylene glycol, glucose, sucrose, and sorbitol.
11. The process according to claim 10 , wherein the binder is selected from one or more of cellulose derivatives, pregelatinized starch, and polyvinylpyrrolidone.
12. The process according to claim 10 , wherein the binder comprises a cellulose derivative selected from one or more of hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropylmethylcellulose, methylcellulose, ethylcellulose, and carboxymethyl cellulose.
13. The process according to claim 1 , wherein the dry estetrol-containing granules have a volume median diameter in a range of from 100 to 4,000 μm.
14. The process according to claim 1 , wherein the one or more tabletting excipients comprise one or more of lactose, mannitol, xylitol, microcrystalline cellulose, starch, croscarmellose sodium, and polyvinyl pyrrolidone.
15. The process according to claim 1 , wherein the solid dosage unit is formed by direct compression or compression molding.
16. The process according to claim 1 , wherein the dosage unit has a weight between 40 mg and 500 mg.
17. The process according to claim 1 , wherein the dosage unit contains the estetrol component in an amount of 0.5-25 wt. % of the dosage unit.
18. The process according to claim 1 , wherein the dosage unit contains 0.3-100 mg of the estetrol component.
19. The process according to claim 1 , wherein the estetrol component is estetrol.
20. The process according to claim 1 , wherein the dosage unit contains a water-soluble carbohydrate in an amount of 50-99.9 wt. %, selected from one or more of maltose, fructose, sucrose, lactose, glucose, galactose, trehalose, xylitol, sorbitol, erythritol, maltitol, mannitol, and isomalt.
21. The process according to claim 20 , wherein the dosage unit contains at least 20 wt. % mannitol.
22. The process according to claim 1 , wherein the dosage unit contains a disintegrating agent in an amount of 0.1-20 wt. %, selected from one or more of modified starches, crosslinked polyvinylpyrrolidone, and crosslinked carmellose.